Bonesupport, a Lund, Sweden-based provider of injectable bone substitutes for orthopedic trauma, bone infections and instrument augmentation related to orthopedic surgery, closed a $14m round of funding.
The round was led by a new investment from a major Scandinavian Pension Fund, with additional participation from existing investors.
The company intends to use the funds to continue to grow global sales and marketing and accelerate expansion of the CERAMENT platform.
Founded in 1999 by Lloyd Diamond, CEO, and Oern R. Stuge, M.D., Executive Chairman, Bonesupport offers Cerament, a synthetic bone substitute clinically proven to remodel into bone within 6-12 months. The CERAMENT™|G is the first CE-marked injectable gentamicin antibiotic eluting ceramic bone graft substitute. It is indicated to promote and protect bone healing in the management of osteomyelitis, (bone infections) in CE marked countries (it is not available in the United States).
The company also has subsidiary locations in the US and Germany.